Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Phase I/II, Clinical Study to Evaluate the Safety, Tolerability and Efficacy of Intrastromal Injection of Genome-editing GEB-101 in Participants With TGFBI-related Corneal Dystrophy

NCT07750678 is registered in ClinicalTrials.gov with GenEditBio Limited as lead sponsor.

NCT NCT07750678
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07750678 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Phase I/II, Clinical Study to Evaluate the Safety, Tolerability and Efficacy of Intrastromal Injection of Genome-editing GEB-101 in Participants With TGFBI-related Corneal Dystrophy
Lead sponsor
GenEditBio Limited
Phase
Phase 1/2
Overall status
Not yet recruiting
Start date
October 31, 2026
Completion date
December 31, 2028
Enrollment
30 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

corneal abnormality, corneal dystrophies, corneal dystrophies, hereditary, hereditary corneal dystrophy